

## Special Issue

# Place of Radiotherapy/Brachytherapy as an Adjuvant or Salvage Treatment in Genitourinary Cancer, Gynecologic Cancer, and Pelvic Sarcoma

### Message from the Guest Editor

Radiotherapy has an important place in the management of urogenital and gynecological tumors, either as an upfront treatment or as an adjuvant in patients treated with surgery and harboring risk factors for locoregional relapse (e.g., endometrial cancer, early stage cervical cancer, and prostate cancer). It is also used as a salvage treatment in patients who relapse despite a primary surgical procedure. The role of radiotherapy as an adjuvant or salvage treatment has evolved over the past years, with the implementation of modern technologies for improving the therapeutic index of radiotherapy/brachytherapy. This Thematic Issue aims at focusing on the place of radiotherapy/brachytherapy as an adjuvant or salvage treatment for genitourinary and gynecological, as well as for pelvic sarcoma.

---

### Guest Editor

Prof. Dr. Cyrus Chargari

Radiotherapy, Gustave Roussy Institute, 94805 Villejuif, France

---

### Deadline for manuscript submissions

closed (15 November 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/78120](https://mdpi.com/si/78120)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)